NBPF11: A Potential Drug Target and Biomarker (G200030)

Target Name: NBPF11

NCBI ID: G200030

NBPF11

NBPF11: A Potential Drug Target and Biomarker

Non-Boding Protein 11 (NBPF11) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the non-coding RNA gene family, which includes proteins that play a wide range of roles in cellular processes such as gene regulation, DNA replication, and RNA processing. NBPF11 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues.

The NBPF11 protein is composed of 215 amino acid residues and has a molecular weight of 23.9 kDa. It has a characteristic Rossmann-fold, which is a type of secondary structure that is formed by the interaction of amino acids. The Rossmann-fold is a common structural motif that is found in proteins that play a critical role in protein-protein interactions, as well as in the regulation of protein stability and activity.

NBPF11 has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. For example, studies have shown that NBPF11 can inhibit the activity of the oncogene transforming growth factor-尾 (TGF-β), which is a well-known regulator of cell growth and differentiation. Additionally, NBPF11 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die naturally in response to external stressors such as exposure to toxins or radiation.

In addition to its role in cellular processes, NBPF11 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that NBPF11 is overexpressed in various cancer tissues, including breast, ovarian, and colorectal cancer. This suggests that NBPF11 may be a useful biomarker for the diagnosis and treatment of these diseases. Additionally, NBPF11 has been shown to be involved in the regulation of cellular signaling pathways, which may be relevant to the development of drug targets for various diseases.

The potential drug target for NBPF11 is its role in the regulation of cell growth and apoptosis. Drugs that are able to inhibit the activity of NBPF11 have been shown to have potential therapeutic benefits for a variety of diseases, including cancer. For example, studies have shown that inhibitors of the NBPF11-TGF-β interaction have the potential to be effective treatments for breast cancer. Additionally, drugs that are able to block the NBPF11-mediated regulation of apoptosis have been shown to have potential therapeutic benefits for diseases such as Alzheimer's disease and Parkinson's disease.

In conclusion, NBPF11 is a protein that has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues. Its role in the regulation of cell growth and apoptosis makes it a promising target for the development of new therapeutic drugs for a variety of diseases. Further research is needed to fully understand the role of NBPF11 in cellular processes and its potential as a drug target and biomarker.

Protein Name: NBPF Member 11

The "NBPF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets